Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Abstract Background The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the guideline-consistent use of DEX was demonstrated in cisplatin. Here, we complete the analysis by assessing the i...

Full description

Bibliographic Details
Main Authors: Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta Letizia, Andrea Misino, Angela Gernone, Erminio Bonizzoni, Sara Pilotto, Sabino De Placido, Emilio Bria
Format: Article
Language:English
Published: BMC 2022-08-01
Series:BMC Cancer
Subjects:
Cisplatin
Dexamethasone
NEPA
Quality of life
Functional living index-Emesis
Chemotherapy-induced nausea and vomiting (CINV)
Online Access:https://doi.org/10.1186/s12885-022-10018-3

Internet

https://doi.org/10.1186/s12885-022-10018-3

Similar Items